Filter By:

Reset
Diabetes and GI Research

PHRI has long investigated the effects of medications and lifestyle approaches on diabetes, with landmark studies such as ORIGIN, which discovered the long-term CV safety of injected insulin. We are looking at causal biomarkers that might help to put type 2 diabetes into remission, as well as metabolic interventions, the epidemiology of obesity, and gastrointestinal (GI) health issues, working with the IMAGINE-SPOR network.

Team Members in Diabetes and GI

Hertzel Gerstein

Deputy Director; Senior Scientist

Hertzel Gerstein
Deputy Director; Senior Scientist

Hertzel Gerstein is Deputy Director, PHRI, and our Senior Scientific Program Lead, Diabetes, as well as a Professor, Medicine, McMaster University. He is also Director of the Division of Endocrinology & Metabolism and Director of the Diabetes Care and Research Program. He has pioneered the application of large simple outcome trials to people with diabetes globally, and developed the concept of dysglycemia as an important risk factor for many of the serious health outcomes that afflict people with an elevated glucose level regardless of diabetes status. He currently leads clinical trials and epidemiological studies related to: a) the prevention and therapy of diabetes and its many consequences, and b) the role of dysglycemia and relative insulin insufficiency on the development of diabetes, cardiovascular disease, cognitive impairment and other chronic conditions. Key studies in which he has played or continues to play a major leadership role include HOPE, MICRO HOPE, ACCORD, DREAM, EpiDREAM, ORIGIN, TIDE, ACE, ELIXA and REWIND.

Hertzel Gerstein has published more than 300 papers, editorials and commentaries, mainly on diabetes-related issues and co-edited the textbook Evidence-Based Diabetes Care. He is an Associate Editor for ACP Journal Club, and is on the editorial board of the Journal of Diabetes and Lancet Diabetes and Endocrinology. He has received several honors including the Canadian Diabetes Association’s Young Scientist Award (1999), Frederick G. Banting award (1999), Charles H. Best award (2007) and Lifetime Achievement Award (2012).

Guillaume Paré

GMEL Director; CRLB Deputy Dir; Senior Scientist

Guillaume Paré
GMEL Director; CRLB Deputy Dir; Senior Scientist

Guillaume Paré is Director of the Genetic and Molecular Epidemiology Laboratory (GMEL) at PHRI, Deputy Director of the Clinical Research Laboratory and Biobank (CRLB), a Senior Scientist at PHRI, a Professor of Pathology and Molecular Medicine, a Professor, Health Research Methods, Evidence and Impact, and a University Scholar at McMaster University.

He holds the Cisco Professorship in Integrated Health Systems. His clinical interests are centered on lipoprotein disorders, obesity and cardiovascular disease prevention, with research interests in cardiovascular genetics, biomarker development and pharmacogenomics. Dr. Paré’s research combines high-throughput biomarker screens with genetics, bioinformatics and epidemiology to identify novel cardio-metabolic biomarkers. He has published more than 200 papers and has been cited over 27,000 times.

A medical biochemist with board certification from the Royal College of Physicians and Surgeons of Canada, Guillaume Paré completed a Master’s in Human Genetics at McGill University under the supervision of renowned geneticist Dr. Thomas Hudson. He further trained in genetic epidemiology with Dr. Paul Ridker at Harvard Medical School.

Zubin Punthakee

Scientist

Zubin Punthakee
Scientist

Zubin Punthakee is an Associate Professor in the Departments of Medicine (endocrinology and metabolism) and Pediatrics, at McMaster University. His research interests are: clinical trials of diabetes management; association between obesity and insulin resistance/diabetes, especially in youth; health care delivery and outcomes during transition from pediatric to adult care; and long-term outcomes of pediatric endocrine diseases.

At PHRI, he has held leadership roles in the TIDE trial, ORIGINALE study and RICH LEGACY study. He has published more than 22 articles, been supported by Research Career Awards from Hamilton Health Sciences and the Department of Medicine at McMaster University, and holds research grants from agencies including the Canadian Institutes of Health Research.

Natalia McInnes

Investigator

Natalia McInnes
Investigator

Natalia McInnes is the Joint Principal Investigator for the Diabetes Remission program at PHRI, and Assistant Professor in the Division of Endocrinology, McMaster University. She has received peer-reviewed research funding from CIHR and Canadian Diabetes Association and is supported by the Medicine Internal Career Award from McMaster University. Her research interests include remission of pre-diabetes and type 2 diabetes, and the relationship between dysglycemia and ectopic fat deposition.

She received her medical degree from the University of British Columbia. After completing her Internal Medicine and Endocrinology training, she pursued MSc in Health Research Methodology at McMaster University.

David Jenkins

Associate Senior Scientist

David Jenkins
Associate Senior Scientist

David Jenkins is a Professor, Departments of Medicine and Nutritional Sciences at the University of Toronto, a staff physician in the division of endocrinology and metabolism, Director of the Clinical Nutrition and Risk Factor Modification Center, and a scientist at the Li Ka Shing Knowledge Institute a of St. Michael’s Hospital.

Educated at Oxford University, he was the first researcher to demonstrate the breadth of metabolic effects of viscous soluble fiber on blood glucose and cholesterol lowering of relevance to prevention and treatment of diabetes and heart disease. David  Jenkins’ studies on combining cholesterol lowering food components (dietary portfolio) have been recognized as creating an effective dietary alternative to drug therapy (statins) for lower risk people.

Paul Moayyedi

Associate Senior Scientist

Paul Moayyedi
Associate Senior Scientist

Professor, Department of Medicine (gastroenterology), and Assistant Dean, Research at McMaster University, Paul Moayyedi is Principal Investigator of the IMAGINE-SPOR study at PHRI, and leads the CIHR Strategy for Patient Oriented Research funded consortium across Canada evaluating impact of diet and the microbiome on inflammatory bowel disease, irritable bowel syndrome and related psychiatric disorders.

He received his medical education at Bristol University, and trained in gastroenterology at Leeds’ General Infirmary, UK. He was awarded a PhD and a Masters in Public Health from the University of Leeds. Moayyedi was a professor of gastroenterology health services research at the University of Birmingham before coming to McMaster to serve as the inaugural Richard Hunt/AstraZeneca Chair of Gastroenterology in 2004. He has been the director of the division of gastroenterology and currently holds the Audrey Campbell Chair of Ulcerative Colitis Research.

Katherine Morrison

Associate Scientist

Katherine Morrison
Associate Scientist

Katherine Morrison is Associate Professor, Department of Pediatrics, McMaster University, and a Principal Investigator for childhood risk factors research at PHRI. She has received various awards including the Excellence in Pediatric Research Award, and a Heart and Stroke Foundation Fellowship in Preventive Cardiology. Katherine is supported in her research by the Canadian Institutes of Health Research, the Heart and Stroke Foundation, the Hamilton Academic Health Sciences Organization, and McMaster Children’s Hospital Foundation.

Neeraj Narula

Associate Scientist

Neeraj Narula
Associate Scientist

Neeraj Narula is Assistant Professor, Medicine, McMaster University, Director, IBD Clinic at McMaster, and staff gastroentereologist at Hamilton Health Sciences. His research interests are clinical epidemiology, nutrition, and interventional trials in inflammatory bowel diseases (IBD), with a special focus on alternative therapies for inflammatory bowel disease. He is evaluating dietary interventions for Crohn’s disease and other alternative ways to modify the course of IBD (i.e. fecal microbiota transplantation).

Neeraj serves as Vice-President for the Canadian IBD Research Consortium. He has completed the Present-Levison advanced IBD fellowship in Mount Sinai Medical Centre in New York, an MPH at Harvard TH Chan School of Public Health in Boston, and his Masters of Public Health at Harvard University.

 

 

Diana Sherifali

Associate Investigator

Diana Sherifali
Associate Investigator

Diana Sherifali is an Associate Professor, School of Nursing, McMaster University, and clinical nurse specialist in the Diabetes Care and Research Program at Hamilton Health Sciences. She is also Director of the McMaster Evidence Review and Synthesis Team based in the School of Nursing. Her research focuses on optimizing the management of diabetes and quality of life of people with diabetes across the lifespan.

She received the inaugural Heather M. Arthur Population Health Research Institute / Hamilton Health Sciences Chair in Inter-Professional Health Research at McMaster University in 2019.

Reema Shah

Research Fellow

Reema Shah
Research Fellow

Reema Shah completed her MD and internal medicine residency at the University of Toronto, and her endocrinology and metabolism residency at McMaster University. After residency, she completed the Clinician Investigator Program at McMaster University and Master of Public Health degree at Harvard University. Reema is interested in clinical research in the area of diabetes and its complications. She is being supervised by Dr. Hertzel Gerstein.

Tara McCready

Program Director

Tara McCready
Program Director

Tara McCready, PhD, oversees a variety of collaborative programs at PHRI, and serves as Project Manager for PHRI research studies and registries.

She was recruited to PHRI as a Program Director for the Canadian Network and Centre for Trials Internationally (CANNeCTIN), a national network funded by the CIHR/CFI Clinical Research Initiative program to improve the prevention and treatment of cardiac and vascular diseases and diabetes.

Previously the Executive Director of the Canadian Maternal, Infant, Child and Youth Research Network, Tara holds a PhD in Biochemistry and a MBA in Technology Commercialization from the University of Alberta.

ongoing

BRAVE

Diabetes and GI

The objective of the BRAVE study is to demonstrate the feasibility of enrolling patients with...

ongoing

IMAGINE

Diabetes and GI

To create a large cohort of patients with Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease...

ongoing

REMIT-iDegLira

Diabetes and GI

REMIT-iDegLira is a multicentre, open-label, randomized controlled trial in patients with recently-diagnosed T2DM. Participants will...

ongoing

REMIT-iGarLixi

Diabetes and GI

The objective of the REMIT-iGarLixi study is to determine if, in patients with recently diagnosed...

completed

ACCORD

Diabetes and GI

The objective of the ACCORD study was to test treatment strategies aimed at reducing cardiovascular...

completed

ACCORDION

Diabetes and GI

The objective of the ACCORDION study was to elucidate and clarify the long-term effects of...

completed

Diabetes Hamilton

Diabetes and GI

The objective of the Diabetes Hamilton study was to learn more about how diabetes affects...

completed

DREAM

Diabetes and GI

The objective of the DREAM study was to evaluate whether ramipril and/or rosiglitazone prevent the...

completed

DREAM ON

Diabetes and GI

The objective of the DREAM ON study was to show that rosiglitazone substantially reduced the...

Back To Top